3 17-02-2020; 24-02-2020 to 31-12-2024 1–2Recruiting NCT04276896;https://clinicaltrials.gov/show/NCT04276896 Function and safety study of SARS-CoV-2 synthetic minigene vaccines Autologous LV-DC vaccine or antigen-specific cytotoxic T-cells 100 Experimental group: 5×106 LV-DC vaccine or 1×108 cytotoxic T-cells as a single infusion via subcutaneous fluids or i.v. injection; may receive additional infusionsControl group: none specified